

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 8, 2024

ABSCI CORPORATION
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-40646
(Commission
File Number)

85-3383487
(I.R.S. Employer
Identification No.)

18105 SE Mill Plain Blvd
Vancouver, WA 98683
(Address of principal executive offices, including zip code)

(360) 949-1041
(Registrant's telephone number, including area code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Common Stock, \$0.0001 par value per share

Trading Symbol(s)
ABSI

Name of each exchange on which registered
The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01 Other Events

On January 8, 2024, Absci Corporation (the "Company") announced that it will present a business update at the 42nd Annual J.P. Morgan Healthcare Conference. A copy of the slides from the presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The presentation is available in the "Events and Presentations" section of the Company's investor relations website at investors.absci.com.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Slides from Absci Corporation's presentation filed on January 8, 2024.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Absci Corporation

Date: January 8, 2024

By: /s/ Sean McClain
Sean McClain
Founder and CEO

abs-ci.

```
from abs-ci import de_novo_model
model = de_novo_model.load_latest()
antigen = model.load_pdb("7olz.pdb",
chain="A")
antibodies = model.predict(antigen, N=300000)
```

```
from abs-ci.library import codon_optimizer
library
= codon_optimizer.reverse_translate(library)
library.to_csv("covid-antibody-designs.csv")
library.to_wet_lab(assay="ACE")
```

```
from abs-ci import lead_opt_model
lead_optimizer = lead_opt_model.load_latest()
library.naturalness =
lead_optimizer.naturalness(library)
lead_optimizer.optimize(library).to_wet_lab(assay="SPR")
```

DRUG CREATION



42ND JP MORGAN HEALTHCARE
CONFERENCE

```
from abs-ci import genetic_algorithm; parameters=["maximize|binding_affinity:pH=7.5", "minimize|binding_affinity:pH=6.0",
"maximize|human_naturalness"]; library = genetic_algorithm.multiparametric_optimization(library, parameters, evolutions=100);
library.to_wet_lab(assays=["ACE", "SPR", "Bioassays"])
```

ABSCI CORPORATION 2024 ALL RIGHTS RESERVED

Disclaimers

Forward-Looking Statements

Certain statements in this presentation that are not historical facts are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements containing the words "will," "may," "anticipates," "plans," "believes," "forecast," "estimates," "expects," "predicts," "advancing," "aim," "potential," and "intends," or similar expressions. We intend these forward-looking statements, including statements regarding our strategy, estimated speed, cost advantages, improved success rates, and expanded intellectual property opportunities from developing therapeutics leveraging our AI drug creation platform, the effective incorporation of our technology in drug design and discovery to accelerate drug development and increase probability of success, advancements toward in silico drug design and creation, research and technology development collaboration efforts, including growing partnership momentum for 2024, potential total dollar value of, and milestone and royalty payments due under, our collaboration agreements, projected costs, prospects, plans and objectives of management, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and we make this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to us and on assumptions we have made. We can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved, and, furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including, without limitation, risks and uncertainties relating to the development of our technology, our ability to secure milestone payments and royalties, our ability to effectively conduct research, drug discovery and development activities with respect to our internal programs and to collaborate with our partners or potential partners with respect to their research, drug discovery and development activities, and our dependence on third parties to support our internal development programs, including for the manufacture and supply of preclinical and clinical supplies of our product candidates or components thereof, along with those risks set forth in our most recent periodic report filed with the U.S. Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.

Market and Statistical Information

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other industry data. These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. We have not independently verified the data generated by independent parties and cannot guarantee their accuracy or completeness.

Trademark usage

This presentation/document/webpage contains references to our trademarks and service marks and to those belonging to third parties. Absci®, the Absci logo mark (A), SoluPro®, Bionic SoluPro®, and SoluPure® are Absci registered trademarks with the U.S. Patent and Trademark Office. We also use various other trademarks, service marks and trade names in our business, including the the Absci AI logo mark (AI), the Unlimit with us mark (Unlimit), the unlimit symbol (unlimit), Bionic protein™, Bionic Enzyme™, Bionic Antibody™, Denovium™, Denovium Engine™, Drug Creation™, Integrated Drug Creation™, HiPrBind™, HiPrBind Assay™, Translating Ideas into Drugs™, Translating Ideas into Impact™, We Translate Ideas into Drugs™, Creating drugs at the speed of AI™, Better biologics for patients, faster™, Breakthrough therapeutics at the click of a button, for everyone™, and We Translate Ideas into Impact™. All other trademarks, service marks or trade names referred to in this presentation/document/webpage are the property of their respective owners. Solely for convenience, the trademarks and trade names in this presentation/document/webpage may be referred to with or without the trademark symbols, but references which omit the symbols should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.



Absci is a Data-First Generative AI Drug Creation Company

Our Integrated AI & Wet Lab Platform
Aims to Engineer
**Better Biologics Faster at
Lower Cost with
Design-in Functionality and Best-in-
Class Properties**

RECENT SUCCESSES

NEW PHARMA PARTNERSHIPS

- "Astrazeneca Types up \$247m AI-enabled Oncology Antibody Design Pact, Joining Absci's list of Pharma Allies" – Fierce Pharma
- "Skin in the Game: Absci Partners with Almirall on Up-to-\$650M Dermatology AI Collaboration" –GEN News

10 NEW ACTIVE PROGRAMS

- Achieved guidance for 2023 with growing partnership momentum for 2024

INTERNAL ASSET PORTFOLIO

- Internal Asset Portfolio focused on cytokine biology
- Lead asset ABS-101, an AI-designed TL1A antibody product candidate

Integrated Wet-Lab Dry-Lab Drug Creation™ Platform

DATA TO TRAIN


Proprietary wet-lab assays generate massive quantities of high-quality data for generative AI model training

WET LAB TO VALIDATE


Scalable wet-lab infrastructure capable of validating **millions** of unique AI-generated designs a week

AI TO CREATE

Advanced generative AI models used to “create” antibodies and next-gen biologics




Proprietary Wet-lab Technologies Generate High-quality Data at Scale




DATA TO TRAIN

Absci's AI capable of creating **billions** of antibody designs for our proprietary models and ACE Assay™ technology to subsequently screen **millions** of ranked antibody sequences in weeks.





Advanced generative AI models to “create” biologics *in silico*




AI TO CREATE

Generative AI models utilizing latest architectural innovations to access a massive $\sim 20^{155}$ sequence search space to design antibody-antigen complex structures and sequences *in silico*



Wet-lab Capable of Validating Millions of AI-Generated Designs in a Week



WET LAB TO VALIDATE

77,000 SqFt+ Wet-Lab to generate scalable data and validate AI-generated designs in rapid iterative **6-week cycles**



FUNCTIONALITY

- Binding Affinity
- Specificity to target(s)
- Potency
- FcRn Recycling

DEVELOPABILITY

- Self association
- Hydrophobicity
- Solubility
- Stability (multiple conditions)

INTEGRATED AI WET-LAB PLATFORM

Leveraging AI Throughout the End-to-End Drug Discovery Process

TARGET DISCOVERY WITH NOVEL APPROACHES



Reverse Immunology for target discovery



ai



ai



AI-GUIDED ANTIBODY DRUG CREATION



De novo antibodies designed by AI



Multi-parameteric optimized antibodies



ai



VALUE DRIVERS

Platform Enables the Potential to Deliver Differentiated Biologics, Faster at Lower Cost

**ACCESS NOVEL
DISEASE BIOLOGY**



Ability to address elusive drug targets, e.g. GPCRs, Ion Channels

ENABLING FIRST-IN-CLASS

**INCREASED
PROBABILITY
OF SUCCESS**



Superior Drug Attributes and Multidimensional optimization creates higher quality biologics

ENABLING BEST IN CLASS & HIGHER PROGRAM NPVS

**REDUCED TIME &
COST TO CLINIC**



2 years and \$14-16M from Target to IND; significant reduction compared to industry estimates

FASTER TIME TO IND

**EXPANDED
INTELLECTUAL
PROPERTY SPACE**



Generates broader IP for First-in-Class therapies and finds new IP for Best-in-Class therapies

ENHANCED IP PROTECTION

RECENT PARTNERSHIPS

Over \$900M + Royalties of Potential Deal Value Signed in the Last 2 Months



DEC 04, 2023

"AstraZeneca Types up \$247m AI-enabled Oncology Antibody Design Pact, Joining Absci's list of Pharma Allies"

-Fierce Pharma




NOV 14, 2023

"Skin in the Game: Absci Partners with Almirall on up-to-\$650 Dermatology AI Collaboration"


-GEN News

ILLUSTRATIVE ECONOMIC STRUCTURE OF A SUCCESSFUL DRUG DISCOVERY PARTNERSHIP



PARTNERSHIPS

Driving Growth Through Industry-Leading Collaborations including 16 Active Programs¹ and 3 Internal Programs




¹ As of December 31, 2023. Trademarks, service marks or trade names referred to herein are the intellectual property of their respective owners. Use of this IP does not imply affiliation, endorsement or sponsorship of any kind.

SELECT PIPELINE HIGHLIGHTS

Internal Pipeline of Potential First-in-Class and Best-in-Class Assets


Focus on *cytokine biology* - first frontier of AI-driven disruption



ABS-101 TL1A DATA HIGHLIGHTS


Clinically Validated Mechanism of Action in Large Underserved Market

TL1A: DR3 SIGNALING CLINICALLY SHOWN TO INDUCE PRO-INFLAMMATORY RESPONSES¹



¹ Adapted from Takedatsu 2008 doi: [10.1053/j.gastro.2008.04.037](https://doi.org/10.1053/j.gastro.2008.04.037)

POTENTIAL RELEVANCE IN WIDE RANGE OF AUTOIMMUNE INDICATIONS



² Wang 2023 <https://pubs.rsos.royalsocietypublishing.org/doi/10.1098/rsos.2022.065186>

³ Dahlhamer, James M., et al. "Prevalence of inflammatory bowel disease among adults aged 18 years—United States, 2015." *Morbidity and mortality weekly report* 65.42 (2016): 1166-1169.

⁴ Evaluate Pharma Oct 2023.



DE NOVO AI-DESIGNED AND AI-OPTIMIZED

- Target to promising candidates in just over 1 year

SUPERIOR PRE-CLINICAL PROFILE AND POTENTIAL FOR SUPERIOR CLINICAL PROFILE


- High Affinity & Potency
- Extended Half life & Longer Dosing Intervals
 - Q8W to once quarterly
- Sub-Q Dosing
 - Low immunogenicity
 - High bioavailability
- Favorable Developability

DIFFERENTIATED INTELLECTUAL PROPERTY


ABS-101 TL1A DATA HIGHLIGHTS

AI Platform Designed Advanced Leads with High Affinity and Superior Potency

HIGH AFFINITY mABs WITH PRESERVED CROSS-REACTIVITY



AI-OPTIMIZED LOW pM AFFINITY TRANSLATES TO SUPERIOR OR EQUIVALENT POTENCY




*Estimated performance of a putative clinical competitor molecule generated for in house comparison.

ABS-101 TL1A DATA HIGHLIGHTS

AI Platform Designed Advanced Leads with Extended Half-life:
Supporting Potential for Significantly Improved Dosing Intervals

EXTENDED HALF-LIFE IN VITRO COMPARED TO CLINICAL COMPETITORS


INCREASED RECYCLING OF ABS-101 LEADS IN CELLULAR FcRn RECYCLING ASSAY¹



¹ Cell-based FcRn recycling assay in HREC-1 cells. Grevys 2018
² Homozygous hFcRn Tg32 mouse model, single dose i.v.
^{*} Initial mouse PK using surrogate molecule (backbone differences from ABS-101-B). Study data pending for final IgG1 mAb.
[#] Estimated performance of a putative clinical competitor molecule generated for in house comparison

PRELIMINARY IN VIVO PK DATA SHOWS POTENTIAL FOR EXTENDED HALF-LIFE

IMPROVED PK PROFILE FOR ABS-101-B IN PK STUDY Tg32 MOUSE MODEL, SINGLE DOSE I.V.²




PARAMETERS	ABS-101-B*	RVT-3101*
t _{1/2} (d)	12.4	6.8
CL (mL/d/kg)	5.83	12.8
V _{ss} (mL/kg)	98.6	109
AUC _{0-∞} (µg·d/mL)	1710	784

ABS-101 TL1A DATA HIGHLIGHTS

AI Platform Designed Leads Span Diverse Set of Epitopes Leading to IP Differentiation

Epitope bins* on TL1A



▶ Absci AI-optimized leads span multiple epitopes

▶ ABS-101 binds a unique epitope on TL1A, differentiating ABS-101 from clinical competitors

* Epitope binning by BLI competition experiment
Estimated performance of clinical competitor reagent generated for comparison

ABS-101 TLIA DATA HIGHLIGHTS

AI Platform Designed ABS-101 Aims for Optimal Therapeutic Profile

ATTRIBUTE	ABS-101 PROGRAM*	MERCK (PROMETHEUS) MK-7240	ROCHE (ROIVANT) RVT-3101	SANOFI (TEVA) TEV-48574
Low Immunogenicity**	✓	✓ ¹	✗ ^{1,5}	—
High Bioavailability	✓	✓ ¹	✗ ^{1,4}	—
Sub-Q autoinjector	✓	✗	✓ ²	✓ ³
Q8W to once quarterly dosing	✓	✗ ^{1,3}	✗ ^{1,3}	✗ ³

* Projected ABS-101 attributes derived from *in silico* and *in vitro* metrics and modeled exposure with ½-life extension

** Low score by 2 *in silico* immunogenicity metrics and low results in ex vivo testing

¹ Based on Phase 2 data

² Expected commercial form factor

³ Once monthly dosing regimen

⁴ 45% BA at 100mg/mL based on Ph2 Data

⁵ Danase et al 2021 (Pfizer Phase 2 data) reports 41 participants out of 50 participants (82%) developing ADA, and 5 (10%) of these developed neutralizing ADA

ABS-101 TL1A DATA HIGHLIGHTS

Projected Timeline to Potential Best-in-Class Molecule

● TODAY

AI-Designed Advanced Leads

- ✓ High Affinity
- ✓ High Potency
- ✓ Long Half-Life
- ✓ Favorable Manufacturability



● INITIATING FEB '24

IND-enabling studies to evaluate

- Sub-Q formulation
- Favorable PK with long half-life
- Low ADA
- High Bioavailability
- High Tolerability (low tox)



● 1Q25

Investigational New Drug (IND) Submission



● 1H25

Initiating Phase 1 Trial



WELL-POSITIONED TO DELIVER

Absci's talent and Infrastructure for Better Biologics Faster, at Lower Cost




Trademarks, service marks or trade names referred to herein are the intellectual property of their respective owners. Use of this IP does not imply affiliation, endorsement or sponsorship of any kind.

~ 160

Unlimiteders with deep experience in AI, drug discovery, immunology, and synthetic biology

Leading AI team with expertise from:



Biologics drug discovery expertise from:



77,000+ Square Feet

State-of-the-art drug creation and wet lab space in Vancouver WA, Absci AI Research (AAIR) lab in NYC, and the Innovation Centre in Zug Switzerland

16

Active Programs*

3

Named Internal Asset Programs*

~\$450M

Capital raised to date

WORLD-CLASS TEAM

Leadership Team of Innovators Across AI and Biotech to Transform Drug Discovery

LEADERSHIP TEAM



SEAN MCCLAIN
Founder, CEO & Director



ANDREAS BUSCH, PHD
Chief Innovation Officer



ZACH JONASSON, PHD
Chief Financial Officer, Chief Business Officer



KARIN WIERINCK
Chief People Officer



JACK GOLD
Chief Marketing Officer



KAREN MCGINNIS, CPA
Lead Independent Director
Former CAO,
Illumina



FRANS VAN HOUTEN
Former CEO,
Royal Philips



SIR MENE PANGALOS, PHD
Former EVP R&D
AstraZeneca



AMARO TAYLOR-WEINER,
PHD
SVP, Chief AI Officer



CHRISTIAN STEGMANN,
PHD
SVP, Drug Creation




CHRISTINE LEMKE, DVM
SVP, Portfolio & Growth Strategy



JENS PLASMEIER, PHD
SVP, Biologics Discovery Technologies



PENELOPE
Chief Morale Officer



AMRIT NAGPAL
Managing Director,
Redmile Group




DAN RABINOVITSJ
Vice President
Connectivity, Meta



JOSEPH SIROSH, PHD
Former CTO, Compass
VP, Amazon & Microsoft



BOARD OF DIRECTORS



UPCOMING CATALYTS &
CONTINUED PARTNERSHIP
MOMENTUM



IND-enabling studies
initiating for ABS-101
(TL1A) Feb '24



in-vivo validation studies
for ABS-301, potential 'first-
in-class' immuno-oncology
asset



Development Candidate
selection for ABS-201;
potential 'best-in-class'
dermatology asset



IND submission for
ABS-101 in 1Q25

Better Biologics **Faster** and
at Lower Cost

'Data to Train', 'AI to Create', and 'Wet
Lab to Validate' in rapid **6-week cycles**

Platform **validated** through industry-
leading partnerships, most recently
with AstraZeneca and Almirall

Internal pipeline of potentially '**best-
in-class**' (TL1A) and
'**first-in-class**' asset programs

